Literature DB >> 1971949

MK-801 and AP5 impair acquisition, but not retention, of the Morris milk maze.

V Heale1, C Harley.   

Abstract

The effects of the NMDA blockers, AP5 and MK-801, were assessed in two spatial tests. AP5 (10 micrograms in 2 microliters ICV, N = 6), or MK-801 (0.07 mg/kg IP, N = 6), significantly increased open-field activity in male Long-Evans rats in two 3-min tests (Days 1 and 2) compared to control groups receiving equal volume saline injections (N = 12). In the Morris milk maze, NMDA blockade significantly impaired acquisition performance on two blocks of six trials, which followed each open-field test. Only control animals showed evidence of acquisition on a drug-free retention test assessing latency to reach the expected platform area and number of crossings in the area on Day 4. Retention was tested in control animals under NMDA blockade on Day 6. There was no effect of NMDA blockade on retention in the Morris milk maze. These results support the hypothesis that NMDA receptors are critical for the initiation of synaptic modification underlying place learning, but are not necessary in synaptic transmission during retrieval of place information.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971949     DOI: 10.1016/0091-3057(90)90140-d

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  24 in total

1.  The effects of aging and genotype on NMDA receptor expression in growth hormone receptor knockout (GHRKO) mice.

Authors:  Kathy Ruth Magnusson; Siba Ranjan Das; Daniel Kronemann; Andrzej Bartke; Peter R Patrylo
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-03-31       Impact factor: 6.053

2.  Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics.

Authors:  Andrea M Bradford; Kevin M Savage; Declan N C Jones; Mikhail Kalinichev
Journal:  Psychopharmacology (Berl)       Date:  2010-07-31       Impact factor: 4.530

3.  Dizocilpine prevents the development of tolerance to ethanol-induced error on a circular maze test.

Authors:  S Rafi-Tari; H Kalant; J F Liu; I Silver; P H Wu
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

4.  Declines in mRNA expression of different subunits may account for differential effects of aging on agonist and antagonist binding to the NMDA receptor.

Authors:  K R Magnusson
Journal:  J Neurosci       Date:  2000-03-01       Impact factor: 6.167

5.  Dopamine-mediated MK-801-induced elevation in food-based extinction responding in rats and associated changes in region-specific phosphorylated ERK.

Authors:  Matthew R Holahan; Melanie J Clarke; Delaney D Hines
Journal:  Psychopharmacology (Berl)       Date:  2010-07-23       Impact factor: 4.530

6.  Phencyclidine disrupts long- but not short-term memory within a spatial learning task.

Authors:  R P Kesner; M Dakis; B L Bolland
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  The NMDA receptor antagonist dizocilpine (MK-801) stereoselectively inhibits morphine-induced place preference conditioning in mice.

Authors:  E Del Pozo; M Barrios; J M Baeyens
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

8.  The effects of aging on N-methyl-D-aspartate receptor subunits in the synaptic membrane and relationships to long-term spatial memory.

Authors:  X Zhao; R Rosenke; D Kronemann; B Brim; S R Das; A W Dunah; K R Magnusson
Journal:  Neuroscience       Date:  2009-05-13       Impact factor: 3.590

9.  Selective Vulnerabilities of N-methyl-D-aspartate (NMDA) Receptors During Brain Aging.

Authors:  Kathy R Magnusson; Brenna L Brim; Siba R Das
Journal:  Front Aging Neurosci       Date:  2010-03-19       Impact factor: 5.750

10.  Effects of MK-801 stereoisomers on schedule-controlled behavior in rats.

Authors:  R F Genovese; X C Lu
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.